00:00As I said, this is the Kee Park.
00:01This is the 35th.
00:04This is the Karpini Time-A-R-O-T-E-R.
00:05The Karpini Fire-A-R-O-T-E-R.
00:07The previous LSCC is done for the previous LSCC.
00:12It is very small and small.
00:15So, the Platelet is very small and small.
00:18It is very small and small.
00:20It is very small.
00:23It is very small.
00:25That's why we look at the investigation of Adam TS-13, which is an enzyme called thrombotic, thrombocytopenic, perfura.
00:36This is a rare disease plus a lower disease.
00:42This is 90% mortality.
00:44We have щitterondocytopenic pain, which can be used as a age.
00:47That is why we did our pénis with red alert groups.
00:59That is why we all have a kidney effect and have its effect on it,
01:07What is what you would like to see in this area is that
01:10There is a small amount of time to add to the little amount of time.
01:14We add a lot of time to add anemia.
01:20So, when you add the same amount of time to the time,
01:22it will be reduced to 4-3 times.
01:28So, we transfer it to the little amount of time to the time.
01:32So what the amount of time is, the amount of time to the time to the time.
01:36So, the platelet will be fine with the plasma exchange, so the plasma will be added to the plasma, so
01:48the plasma will be added to the plasma.
01:55The weight loss of the weight loss of the weight loss is a single.
01:59The weight loss will be the volume of theлюx and a staff and all the weight loss.
02:11Now, we have the platelets for almost 20,000.
02:20So, this was how it was possible.
02:23So, these products are very costly.
02:28If you look at that,
02:30This is the case of auto-antibodies, steroids, retuximab, inno-globalin,
02:36these are very important things.
02:40This is how we are doing it.
02:43We have a copy of the virus.
02:47This is not the case of the virus,
02:50or the virus, or the virus, or the virus.
02:55This is the case of the virus.
02:56This is what we have done.
02:59We have helped many departments.
03:02For example, we have to work with microvials,
03:08along with the OG department of course.
03:12We have to work with Transfusion Medicine.
03:14We have to work with them.
03:18We have to work with them.
03:20We have to work with us.
03:24Microbology, Biochemistry, Pathology.
03:26We have to work with them.
03:29We have done a lot of tests.
03:30The tests are the same.
03:32We have to work with Emoglobin.
03:34We have to work with Emoglobin.
03:37It is a good treatment for everyone.
03:41It was only possible because of the team work.
03:46It was a very difficult treatment.
03:48It was a very difficult treatment for us.
03:49We have to work with the treatment.
03:51treatment is because of the treatment.
03:55And the whole team worked earlier to detect the treatment.
04:01So, if they were to get a level, they would be able to get a level,
04:06they would be able to get a level.
04:09There are many paths here.
04:16This is not a defect.
04:20This is a defect that has a plate.
04:23If you know this, there are triggers.
04:27This is a pregnancy set trigger.
04:30Sometimes, first pregnancy is a trigger.
04:32Second pregnancy is a trigger.
04:34So, that's why we know that.
04:39That's why we can't fix it.
04:40If we can fix it, we can fix it and fix it.
04:43Then, we can fix it and fix it.
04:46So, we can fix it and fix it.
04:50We have a whole exon sequencing.
04:53It is not congenital.
04:56It is acquired.
04:57It is acquired.
04:58This is why we said that the kidney has changed.
05:02This is why the kidney is affected.
05:05Now, we have to fix it and fix it.
05:09So, we have to fix it and fix it.
05:09Now, we have to fix it and fix it.
05:14Now, we have to fix it.
05:23Port guillover
05:23So, we don't have to fix it properly.
05:23This is a new effect against kidney Chunvay.
05:23Now, we know when evaluating and followed up.
Comments